The starting dose chosen for the phase 1/2 study was one predicted to be safe and to double CSF progranulin to achieve normal physiological levels, based on the results from the FTD-GRN mouse model and from NHP toxicology studies. This evidence concerns the gene GRN and frontotemporal dementia.